Please assess the completion status of the following clinical trial:

Trial Title: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study related procedures~* Inoperable, Gastro-Entero-Pancreatic-Neuroendocrine Tumour G1 or G2 (Proliferation Index, Ki67-Index: 0 to ≤20%) confirmed by pathological/histological assessment~* Progressive disease within 12 months before inclusion (RECIST 1.1: increase of \>20% tumour load; by Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)~* Measurable disease according to RECIST 1.1.~* Metastatic disease confirmed by CT/MRI.~* Functioning or non-functioning NET (G1, G2).~* Positive Octreo-Scan (≥ Grade 2 Krenning scale) or positive DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-TATE (Tyr3-Thre8-Octreotide or DOTA-Tyr3-octreotate)/TOC (Tyr3-octreotide) -PET (Positron-Emission-Tomography) -CT within 12 months prior to screening~Exclusion Criteria:~* Has the diagnosis of Insulinoma~* Has a diagnosis of a multiple endocrine neoplasia (MEN)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lanreotide Autogel 120mg & Temozolomide (Type: EXPERIMENTAL): Combination phase for first 6 months: Lanreotide Autogel 120 mg and Temozolomide.~Followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months of no treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).